Key result
Ivabradine (3 μM) significantly reduced heart rate by 35 ± 5% and increased stroke volume by 39 ± 9% while preserving energy substrate metabolism in ex vivo healthy normoxic working mouse hearts.
Why the study?
Does ivabradine reduce heart rate while preserving energy substrate metabolism compared to metoprolol in an ex vivo mouse heart model?
Does ivabradine reduce heart rate while preserving energy substrate metabolism compared to metoprolol in an ex vivo mouse heart model?
Ivabradine selectively reduces heart rate while preserving cardiac energy substrate metabolism in healthy working mouse hearts, unlike metoprolol which impairs both cardiac function and glycolysis.
Answers are grounded in this paper and cite their sources.
Ivabradine may preserve metabolism better than metoprolol in healthy hearts; leaves open translation to diseased or in vivo models.
Heart rate reduction (HRR) is an important target in the management of patients with chronic stable angina. Most available drugs for HRR, such as β-blockers, have adverse effects, including on cardiac energy substrate metabolism, a well-recognized determinant of cardiac homeostasis. This study aimed at 1) testing whether HRR by ivabradine (IVA) alters substrate metabolism in the healthy normoxic working heart and 2) comparing the effect of IVA with that of the β-blocker metoprolol (METO). This was assessed using our well-established model of ex vivo mouse heart perfusion in the working mode, which enables concomitant evaluation of myocardial contractility and metabolic fluxes using (13)C-labeled substrates. Hearts were perfused in the absence (controls; n = 10) or presence of IVA (n = 10, 3 μM) with or without atrial pacing to abolish HRR in the IVA group. IVA significantly reduced HR (35 ± 5%) and increased stroke volume (39 ± 9%) while maintaining similar cardiac output, contractility, power, and efficiency. Effects of IVA on HR and stroke volume were reversed by atrial pacing. At the metabolic level, IVA did not impact on substrate selection to citrate formation, rates of glycolysis, or tissue levels of high-energy phosphates. In contrast, METO, at concentrations up to 40 μM, decreased markedly cardiac function (flow: 25 ± 6%; stroke volume: 30 ± 10%; contractility: 31 ± 9%) as well as glycolysis (2.9-fold) but marginally affected HR. Collectively, these results demonstrate that IVA selectively reduces HR while preserving energy substrate metabolism of normoxic healthy working mouse hearts perfused ex vivo, a model that mimics to some extent the denervated transplanted heart. Our results provide the impetus for testing selective HRR by IVA on cardiac substrate metabolism in pathological models.
No takes yet. Share an insight, caveat, or question.
Lauzier et al. (2011) studied Healthy normoxic working hearts (n=20). Ivabradine vs. Control (absence of ivabradine) and Metoprolol was evaluated on Heart rate, stroke volume, and metabolic fluxes. Ivabradine (3 μM) significantly reduced heart rate by 35 ± 5% and increased stroke volume by 39 ± 9% while preserving energy substrate metabolism in ex vivo healthy normoxic working mouse hearts.
Synapse has enriched 10 related papers. Consider them for comparative context: